Umecrine Cognition will attend BIO-Europe Spring® 2024 in Barcelona

STOCKHOLM – March 18, 2024. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Barcelona, Spain. The meeting takes place March 18–20th and is expected to gather over 3,700 attendees representing the global life science industry. During the meeting, Umecrine Cognition will meet with potential global partners to further expedite the development of golexanolone in diseases with symptoms stemming from neuroinflammation.

BIO-Europe is one of the premier hosts of partnering events in the global life science community. Annually, their meetings gather company executives and representatives from across the world to promote scientific and business collaborations. Anders Karlsson, CEO of Umecrine Cognition, and Magnus Doverskog, SVP and CSO, will attend the meeting.

“The company is heading into an exciting phase with developmental activities ongoing in several therapeutic areas. Our lead drug candidate golexanolone is currently undergoing clinical evaluation against primary biliary cholangitis in a Phase 2 study, which is set to expand to new research centers in eight countries as the study progresses to its second part. In parallel, a recent review article that covers the molecular interplay between GABA signaling and neuroinflammation, and highlights golexanolone’s therapeutic potential in chronic liver diseases, was published in Frontiers of Pharmacology. Additionally, we’re happy to also bring new preclinical insights widening the body of scientific data that illuminates golexanolone’s potential to normalize debilitating cognitive and motor symptoms in Parkinson’s disease,” says Anders Karlsson, CEO of Umecrine Cognition.

For further information, please contact:

Anders Karlsson, CEO, Umecrine Cognition AB
Phone: +46 70 – 918 00 10, e-mail: [email protected]

About Umecrine Cognition AB

Umecrine Cognition AB develops a completely new class of pharmaceuticals against neurological disturbances in the brain that may arise as a consequence of several underlying diseases, leading to strongly reduced cognitive functions and wakefulness. Results from an internationally recognized clinical Phase 2 study indicates that the company’s most advanced drug candidate, golexanolone, normalizes the brain’s signaling and improves cognition as well as wakefulness in patients diagnosed with hepatic encephalopathy. The continued drug development will initially focus on patient groups whose symptoms arise from chronic liver diseases. The mode of action is however relevant in a number of other indications. For more information, visit